A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.

Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.

Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.